Drug Discovery World

OCTOBER 11, 2022

The authorisation is based on data from the SURPASS Phase III global clinical development programme: five global studies involving 6263 patients. . Reductions in body weight were also demonstrated. . The post New class of treatment approved for diabetic patients in the US appeared first on Drug Discovery World (DDW).

Insulin 52

Insulin Medicine Clinical Development Production 52

BioTech 365

MARCH 31, 2021

Million Grant Award From Innovate UK Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin CAMBRIDGE, United Kingdom, March 31, 2021 … Continue reading → Arecor Receives £2.8 Million Grant Award From Innovate UK Arecor Receives £2.8

Insulin 40

Insulin Clinical Development Production Development 40

Drug Discovery World

MARCH 1, 2024

We look forward to progressing this important therapy into further clinical development later this year. ” Activation of the GLP-1 receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both.

Insulin 52

Insulin Trials Clinical Development Drugs 52

Pharmaceutical Technology

DECEMBER 22, 2022

The company is a clinical-stage biopharmaceutical startup that uses its artificial intelligence (AI)-enabled platform to measure brain biomarkers, including electroencephalogram (EEG) activity and behavioural patterns, wearable data, genetics and other factors, to drive targeted drug development in mental health. Civica JAAQ Sanofi.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

DECEMBER 15, 2020

The Phase III trial evaluated the use of the diabetes vaccine Diamyd ® , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. People with type 1 diabetes cannot produce insulin.

Development 40

Development Insulin Drugs Clinical Trials 40

pharmaphorum

FEBRUARY 21, 2022

Oral, non-steroidal mineralocorticoid receptor (MR) antagonist Kerendia claimed its first regulatory approval in the US last summer, the culmination of several years of clinical development and a hefty investment in three large-scale clinical trials.

Drugs 122

Drugs Trials Insulin FDA Approval 122

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Drugs 59

Drugs Licensing Licensing Protein 59

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. .

Vaccination 98

Vaccination Vaccine Manufacturing Production 98

Delveinsight

AUGUST 20, 2020

Generating insulin-producing pancreatic beta cells from stem cells to substitute those damaged by the immune system is a promising approach for diabetes treatment. Nipocalimab is in clinical development in myasthenia gravis , warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn indications.

Gene Therapy 52

Gene Therapy Research Gene Antibody 52

The Pharma Data

JANUARY 7, 2021

In addition, icosabutate lowered triglyceride levels, improved insulin resistance and lowered hsCRP by an impressive 50%, biomarker changes that improve the patient’s cardiovascular risk profile. A Phase 2b study was initiated in July 2019 (ICONA) to study the efficacy of icosabutate in NASH.

Engineer 40

Engineer Insulin Development Licensing 40

Delveinsight

JULY 21, 2021

Apart from approved therapies, at present several of the promising candidates are in the pivotal stage of clinical development, which is expected to enter the market in the near future. Type 1 Diabetes is a chronic condition in which the pancreas produces little or no insulin. It is also known as insulin-dependent diabetes.

Pharma Companies 94

Pharma Companies Marketing Insulin Development 94

pharmaphorum

MAY 21, 2021

Based in Cambridge, Arecor has proprietary formulation technology and plans to enter development partnerships and licence out drugs to big pharma companies, looking for milestone payments and royalties as they progress through the development process and on commercialisation.

Insulin 52

Insulin Drugs Production Marketing 52

The Pharma Data

SEPTEMBER 11, 2021

. “This Breakthrough Therapy designation underscores the potential of Jardiance to help fill a critical need for a clinically proven treatment for people with this highly prevalent, difficult-to-treat condition,” said Mohamed Eid, M.D., vice president, Product Development, Lilly. drowsiness. irritability. fast heartbeat.

Medicine 52

Medicine Insulin FDA Approval Trials 52

The Pharma Data

DECEMBER 13, 2020

7.1%) levels were well controlled, and in this context, significant placebo-adjusted decreases were observed in both glycemic parameters along with improvements in commonly used fasting indexes of insulin sensitivity (HOMA-IR and QUICKI scores). In the T2DM patients, baseline fasting glucose (121-144 mg/dL) and HbA1c (6.6-7.1%)

Trials 52

Trials In-Vitro Insulin Protein 52

XTalks

AUGUST 2, 2023

It is a dipeptidyl peptidase-4 inhibitor that keeps insulin levels stable and reduces the amount of glucose produced by the body. In partnership with Seagen, Sanofi will design, develop and commercialize ADCs for three cancer targets using Sanofi’s proprietary monoclonal antibody technology and Seagen’s proprietary ADC technology.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Delveinsight

AUGUST 25, 2021

There are 15 drugs in the registrational/Phase III including its another important immunological drug, Skyrizi (risankizumab) which is approved for Psoriasis , but in the mid-to-late stage clinical development for Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis. It generated a revenue share of 9.8% (USD 4.2 billion).

Vaccination 98

Vaccination Vaccine Sales Drugs 98

The Pharma Data

NOVEMBER 2, 2020

On average, people started eating fewer calories after a week, and saw their “good” HDL cholesterol increase while their levels of “bad” LDL cholesterol, insulin and triglycerides all fell. vice president, clinical development, Principia Biopharma, South San Francisco; Donna Ryan, M.D., More information.

Antibody 52

Antibody Drugs Hormones Insulin 52

Drug Discovery World

JULY 13, 2023

There are various schemes in force that allow patients access to unlicensed medicines that are in the late stages of clinical development (i.e., This can be particularly important in Low- or Middle-Income Countries (LMICs) where access to medicines or supply is limited.

Drugs 94

Drugs Medicine Regulation Licensing 94

The Pharma Data

JULY 8, 2021

. “No approved therapies have been clinically proven to improve outcomes specifically for people with HFpEF, leaving a significant unmet medical need in this already prevalent and increasingly common form of heart failure,” said Mohamed Eid, M.D., vice president, Product Development, Lilly. Source link: [link].

Trials 52

Trials Doctors Doctor Medicine 52

The Pharma Data

JUNE 28, 2021

The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 19,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

Clinical Trials 40

Clinical Trials Clinical Trials Hormones Trials 40

The Pharma Data

DECEMBER 15, 2020

Anokion is responsible for preclinical activities and Phase I clinical development of partnered programs, and Bristol Myers Squibb will fund subsequent trials and commercial activities at clinical proof-of-concept.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

The Pharma Data

JULY 23, 2021

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

MARCH 11, 2021

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

APRIL 4, 2023

Initiate treatment with insulin as clinically indicated. This expands the use of KEYTRUDA-based regimens to more patients with advanced urothelial carcinoma and demonstrates the value of collaboration in creating new combination approaches for patients in need of more options.” Withhold KEYTRUDA depending on severity.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

The Pharma Data

JUNE 28, 2021

The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 19,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

Insulin 52

Insulin Clinical Trials Clinical Trials Hormones 52

The Pharma Data

DECEMBER 2, 2020

The new plant will as a first priority produce recombinant GAD65, the active pharmaceutical ingredient in the therapeutic diabetes vaccine Diamyd ® currently in late-stage clinical development. About Diamyd Medical Diamyd Medical develops therapies for type 1 diabetes.

Production 52

Production Insulin Vaccination Vaccine 52

The Pharma Data

MARCH 5, 2021

The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 13,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Hormones 52